article: By . Rachel Reilly . PUBLISHED: . 06:19 EST, 26 April 2013 . | . UPDATED: . 06:46 EST, 26 April 2013 . Research into a new HIV vaccine has been halted after experts found it to be of no use. The U.S. government stopped trials of the experimental HIV vaccine after an independent review found it did not prevent HIV infection or reduce the amount of HIV in the blood. The research, started in 2009, it is just the latest in a series of failed attempts to develop a vaccine for the virus. The study, called HVTN 505, had enrolled 2,504 volunteers in 19 U.S. cities. Scientists are trying to develop a vaccine for the HIV virus but progress is slow . ‘This trial has provided a clear, swift answer about a specific vaccine strategy,' Mitchell Warren, executive director of the nonprofit group AVAC: Global Advocacy for HIV Prevention, told Reuters. It's not the answer we hoped for, but the search doesn't end here. ‘Researchers need to unpack the data from this trial to understand more about why this strategy didn't prevent infection.’ The review board has recommended that no further vaccinations be given. The National Institutes of Allergy and Infectious Disease, which sponsored the study, said it would continue to follow study participants to further evaluate the trial data. The HVTN 505 trial tested a two-part vaccine strategy designed to first prime the immune system and then provide a vaccine 'boost'. The vaccine itself was based on a common cold virus that was used to sneak HIV genes into the body and grab the attention of the immune system. So far, there are no vaccines approved to prevent infection with the human immunodeficiency virus or HIV, the virus that causes AIDS. Several HIV trials are still underway or in planning stages, including a follow-up to a Thai trial which in 2009 showed a vaccine combination cut HIV infections by 31.2 percent. Killer: The HIV virus attacks the body's immune system . Although the finding was not strong enough to approve the vaccine, it offered the first glimpse that a vaccine could work. Both of these vaccines - the one in the Thai study and the HVTN 505 study - are largely designed to train immune system cells known as T-cells to recognize and kill cells already infected with HIV. Researchers are studying other approaches, including vaccines that activate powerful antibodies to prevent HIV from infecting cells in the first place. Matthew Rose, a vaccine advocate for AVAC who participated in the HVTN 505 study, said he remains hopeful in the search for a vaccine. 'These results do not change the fundamental view that an AIDS vaccine remains critical to any long-term strategy to end the AIDS epidemic,' he said.
highlights: Study called HVTN 505 was found not to prevent infection or reduce levels of virus in blood . Research is just one of many failed attempts to develop a vaccination for disease .
id: 513550ca516c3abaa9b87a1bf9e36735dbc0cabf
chatgpt: A recent study called HVTN 505 has been found to be ineffective in preventing the spread of a particular disease, despite its initial high hopes. The research was based on developing a vaccination for the disease but has since been shown to be an unsuccessful attempt. The study, which was conducted by a team of researchers, looked to reduce the levels of the virus in the blood of those infected with the disease. However, the results showed that HVTN 505 was unable to achieve its primary objective, leading to disappointment in the medical community. According to the researchers, the failure of the study is a huge setback in the fight against the disease. The news has sparked concern among experts who were eagerly hoping for positive results. The study is just one of many failed attempts to develop a vaccine for the disease. Despite several efforts, developing a vaccine has proven to be challenging due to the complexity of the disease and its rapid spread. Scientists and health officials have been pushing for the development of a vaccine for the disease for decades, and have invested heavily in research and development activities. Despite their efforts, the success rate has been relatively low, and many of the vaccines that have been developed have failed in their crucial role. This latest study highlights the challenges that researchers face in developing vaccines that work effectively. The results shed light on the intricate nature of the disease, which may require a more targeted approach. Despite the disappointing results, researchers have vowed to continue searching for a cure for the disease, with a renewed focus on developing a more effective vaccine. Medical experts have emphasized the need for continued efforts in this area, noting that the disease is a deadly one that continues to spread rapidly across the globe. In conclusion, the results of the HVTN 505 study are a setback for the medical and scientific communities that were eager for positive outcomes. The challenges associated with developing a vaccine for the disease highlight the complex nature of the illness and the ongoing need for continued research. Despite these challenges, the researchers remain resolute in their quest to find a cure for the disease, and their efforts will no doubt continue to be supported by the medical community as they seek to tackle this global health issue.